ENANTA PHARMACEUTICALS, INC Increase Decrease In Operating Lease Liability
ENANTA PHARMACEUTICALS, INC (ENTA) reported Increase Decrease In Operating Lease Liability of -$2.25 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-12
- ENANTA PHARMACEUTICALS, INC increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$880.00K.
- ENANTA PHARMACEUTICALS, INC increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$533.00K, a 174.13% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$834.00K, a 157.72% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$147.00K, a 103.75% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC increase decrease in operating lease liability for fiscal 2025 was $1.24M, a 75.23% decline from fiscal 2024.
- ENANTA PHARMACEUTICALS, INC increase decrease in operating lease liability for fiscal 2024 was $4.99M.
- ENANTA PHARMACEUTICALS, INC increase decrease in operating lease liability for fiscal 2023 was -$2.57M.
- ENANTA PHARMACEUTICALS, INC increase decrease in operating lease liability for fiscal 2022 was -$3.71M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$880.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12 | -$1.41M derived: sum of 2 quarters · filed 2026-08-12 | -$2.25M 10-Q · filed 2026-08-12 | -$2.39M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$533.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | -$1.37M 10-Q · filed 2026-05-13 | -$1.51M derived: sum of 3 quarters · filed 2026-05-13 | -$2.29M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$834.00K 10-Q · filed 2026-02-11 | -$981.00K derived: sum of 2 quarters · filed 2026-02-11 | -$1.76M derived: sum of 3 quarters · filed 2026-08-12 | -$1.04M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-09-30 | -$147.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | -$927.00K derived: sum of 2 quarters · filed 2026-08-12 | -$208.00K derived: sum of 3 quarters · filed 2026-08-12 | $1.24M 10-K · filed 2025-11-19 |
| 2025-06-30 | -$780.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12 | -$61.00K derived: sum of 2 quarters · filed 2026-08-12 | $1.38M 10-Q · filed 2026-08-12 | $5.30M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $719.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | $2.16M 10-Q · filed 2026-05-13 | $6.08M derived: sum of 3 quarters · filed 2026-05-13 | $9.29M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.45M 10-Q · filed 2026-02-11 | $5.36M derived: sum of 2 quarters · filed 2026-02-11 | $8.58M derived: sum of 3 quarters · filed 2026-02-11 | $7.46M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-09-30 | $3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | $7.13M derived: sum of 2 quarters · filed 2025-11-19 | $6.02M derived: sum of 3 quarters · filed 2025-11-19 | $4.99M 10-K · filed 2025-11-19 |
| 2024-06-30 | $3.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-13 | $2.10M derived: sum of 2 quarters · filed 2025-08-13 | $1.08M 10-Q · filed 2025-08-13 | -$346.00K derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-03-31 | -$1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14 | -$2.14M 10-Q · filed 2025-05-14 | -$3.56M derived: sum of 3 quarters · filed 2025-11-19 | -$4.57M derived: sum of 4 quarters · filed 2025-11-19 |
| 2023-12-31 | -$1.02M 10-Q · filed 2025-02-12 | -$2.45M derived: sum of 2 quarters · filed 2025-11-19 | -$3.45M derived: sum of 3 quarters · filed 2025-11-19 | -$2.87M derived: sum of 4 quarters · filed 2025-11-19 |
| 2023-09-30 | -$1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | -$2.43M derived: sum of 2 quarters · filed 2025-11-19 | -$1.85M derived: sum of 3 quarters · filed 2025-11-19 | -$2.57M 10-K · filed 2025-11-19 |
| 2023-06-30 | -$1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-07 | -$425.00K derived: sum of 2 quarters · filed 2024-08-07 | -$1.14M 10-Q · filed 2024-08-07 | -$1.61M derived: sum of 4 quarters · filed 2024-11-27 |
| 2023-03-31 | $580.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-08 | -$137.00K 10-Q · filed 2024-05-08 | -$608.00K derived: sum of 3 quarters · filed 2024-11-27 | -$1.34M derived: sum of 4 quarters · filed 2024-11-27 |
| 2022-12-31 | -$717.00K 10-Q · filed 2024-02-08 | -$1.19M derived: sum of 2 quarters · filed 2024-11-27 | -$1.93M derived: sum of 3 quarters · filed 2024-11-27 | -$2.96M derived: sum of 4 quarters · filed 2024-11-27 |
| 2022-09-30 | -$471.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-27 | -$1.21M derived: sum of 2 quarters · filed 2024-11-27 | -$2.25M derived: sum of 3 quarters · filed 2024-11-27 | -$3.71M 10-K · filed 2024-11-27 |
| 2022-06-30 | -$737.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-08 | -$1.77M derived: sum of 2 quarters · filed 2023-08-08 | -$3.23M 10-Q · filed 2023-08-08 | |
| 2022-03-31 | -$1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-09 | -$2.50M 10-Q · filed 2023-05-09 | ||
| 2021-12-31 | -$1.46M 10-Q · filed 2023-02-08 | |||
| 2021-09-30 | -$5.88M 10-K · filed 2023-11-22 | |||
| 2020-09-30 | -$3.54M 10-K · filed 2022-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |